ReviewCancer innovation2026
Advances in the Research of Nasopharyngeal Carcinoma: A Perspective.
Review in Cancer innovation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in the Research of Nasopharyngeal Carcinoma: A Perspective.Cancer innovation · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The year 2025 marked significant advances in precision medicine for nasopharyngeal carcinoma (NPC). This review summarizes recent advances in treatment strategies aimed at addressing longstanding challenges in NPC management, including treatment-related toxicity, therapeutic resistance, and the limited precision of risk stratification. For locoregionally advanced NPC, a novel efficacy-enhancing and toxicity-minimizing strategy has emerged: toxicity minimizing involves replacing toxic concurrent cisplatin chemotherapy with PD-1 blockade, achieving superior safety while maintaining non-inferior 3-year failure-free survival; meanwhile efficacy-enhancing employs adjuvant immunotherapy to improve survival specifically in high-risk patients, supporting the transition toward risk-adapted strategies. In radiotherapy, international consensus guidelines recommend reducing target volumes and sparing normal tissues to minimize side effects. For recurrent or metastatic NPC, antibody-drug conjugates(ADCs) and novel immunotherapeutic combinations show promise in overcoming treatment resistance and expanding therapeutic options. Furthermore, advances in artificial intelligence and deeper understanding of resistance mechanisms are accelerating clinical innovation. Collectively, these advances underscore the ongoing shift toward reduced toxicity, improved efficacy, and greater precision in the management of NPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.